EUVIMEDEUVIMED entdecken
Open Access

Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis

Sunish Shah iD, Lloyd Clarke, Matthew W Davis, Jeffrey E Topal, Ryan K Shields iD

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Sunish Shah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Pseudomonas Infections, Anti-Bacterial Agents, Endocarditis, Bacterial, Pseudomonas aeruginosa. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDA NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate clinical outcomes of patients with Pseudomonas endocarditis and identify factors associated with treatment failure.

Methods

Adult patients meeting definitive Duke’s criteria for Pseudomonas endocarditis at 11 hospitals were identified between May 2000 and February 2024. Failure was defined as death or microbiological failure by day 42. First-line therapy consisted of cefepime, piperacillin/tazobactam, ceftazidime or ceftolozane/tazobactam alone or in combination.

Results

Forty-eight patients met inclusion criteria; 29% were persons who inject drugs and 13% were organ transplant recipients. Pseudomonas aeruginosa was the causative species in 98% of cases. Patients who experienced 42 day cure were more likely to be initially managed with first-line β-lactam agents compared with those who experienced clinical failure (97% versus 62%, P = 0.004). Treatment with first-line β-lactams was associated with shorter time to treatment initiation and a lower likelihood of infection due to MDR Pseudomonas spp. In the univariate model, patients who experienced 90 day mortality were more likely to have prosthetic valve endocarditis (57% versus 24%, P = 0.02), an intracardiac complication (36% versus 9%, P = 0.04) and a higher median (IQR) Pitt bacteraemia score [2.5 (2–3.8) versus 1 (0–2), P = 0.048]. Combination therapy did not improve clinical outcomes but did increase the rate of adverse effects resulting in drug discontinuation compared with monotherapy, (21% versus 0%, P = 0.08).

Conclusions

This is the largest study of Pseudomonas endocarditis to date. We identified improved clinical outcomes when cefepime, piperacillin/tazobactam, ceftazidime or ceftolozane/tazobactam were used for initial treatment. We did not identify a clinical benefit for combination treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas InfectionsAnti-Bacterial AgentsEndocarditis, BacterialPseudomonas aeruginosaHumansMaleFemaleMiddle AgedAdultAgedTreatment OutcomeTazobactamRetrospective StudiesTreatment FailurePiperacillin, Tazobactam Drug CombinationCephalosporins

Substanzen

Anti-Bacterial AgentsTazobactamceftolozane, tazobactam drug combinationPiperacillin, Tazobactam Drug CombinationCephalosporins

Autor:innen und Institutionen

  • Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA.
  • Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

ORCID-Profile: Sunish Shah, Ryan K Shields

Förderung

  • NIAID NIH HHS
  • NIDA NIH HHS
  • NIH

Zitieren

APA

Shah, S., Clarke, L., Davis, M. W., Topal, J. E., & Shields, R. K. (2024). Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae205

Vancouver

Shah S, Clarke L, Davis MW, Topal JE, Shields RK. Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae205

BibTeX
@article{Shah2024,
  author = {Shah, Sunish and Clarke, Lloyd and Davis, Matthew W and Topal, Jeffrey E and Shields, Ryan K},
  title = {Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae205}
}
Kostenlos starten →